Fact sheet: AXA WF Fram Health EUR

Fund information
Fund name
AXA World Funds Framlington Health F Cap USD
Fund manager company
AXA Investment Managers
Fund type
Offshore Fund
Fund managers
  • Linden Thomsonsince 31/07/2015
  • Dani Saurympersince 31/07/2015
Fund objective
The Sub-Fund seeks to achieve long-term capital growth measured in USD by investing in equities and equity related instruments issued by companies engaged in healthcare and medical products and services worldwide.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
8.7%
1 Year rank in sector
25/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.17%
Fund size
£96m (£97m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
134
Top in this sector
Fund name1 Year
Polar Capital Biotechnology32.7%
Pictet Biotech31.9%
Franklin Biotech Disc26.1%
UBS (L)E-Btech$24.4%
BB Medtech23.9%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA72.4%
    UK10.9%
    Switzerland5.1%
    Germany3.4%
    Japan2.7%
  • Biotechnology/Medical30.7%
    Pharmaceuticals26.9%
    Health Care19.6%
    Healthcare & Medical Products16.7%
    Money Market1.8%
  • US Equities72.4%
    UK Equities10.9%
    Swiss Equities5.1%
    German Equities3.4%
    Japanese Equities2.7%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund5.9%9.8%0.5%8.7%16.7%87.4%
Sector7%6.9%5.6%14.5%20.4%109%
Rank within sector25 / 317 / 3125 / 3125 / 3117 / 2620 / 24
Quartile4th1st4th4th3rd4th
Calendar performance
 YTD - 20172016201520142013
Fund9.3%-10%6%22%36.4%
Sector9.6%-9.9%7.2%28.1%41%
Rank within sector18 / 3115 / 3120 / 2920 / 2614 / 24
Quartile3rd2nd3rd4th3rd
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
0.46
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
0.8
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.16
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
13.92
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
6.23
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.11
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.86
Price movement
52 week high234.65
52 week low201.53
Current bid price-
Current offer price-
Current mid price228.31
Region
1USA72.35%
2UK10.87%
3Switzerland5.08%
4Germany3.37%
5Japan2.69%
6Belgium2.27%
7Money Market1.21%
8Netherlands1.16%
9Israel1.01%
Industry sector
1Biotechnology/Medical30.7%
2Pharmaceuticals26.9%
3Health Care19.61%
4Healthcare & Medical Products16.71%
5Money Market1.75%
6Hospital1.67%
7Food & Drug Retailers1.43%
8Conglomerates1.23%
Asset type
1US Equities72.35%
2UK Equities10.87%
3Swiss Equities5.08%
4German Equities3.37%
5Japanese Equities2.69%
6Belgian Equities2.27%
7Money Market1.21%
8Dutch Equities1.16%
9Israeli Equities1.01%
Individual holdings
1ROCHE HLDG AG5.08%
2UNITEDHEALTH GROUP INC4.82%
3GLAXOSMITHKLINE PLC4.35%
4ALLERGAN PLC4.34%
5CELGENE CORP4.19%
6GILEAD SCIENCES INC4.13%
7MEDTRONIC PLC3.32%
8AMGEN INC3.23%
9LILLY (ELI) & CO3.1%
Management
Fund manager group
AXA Investment Managers
Fund manager company
AXA Investment Managers
Fund type
Offshore Fund
Fund objective
The Sub-Fund seeks to achieve long-term capital growth measured in USD by investing in equities and equity related instruments issued by companies engaged in healthcare and medical products and services worldwide.
Benchmark
  • MSCI World Healthcare
Investment style
Growth
Investment method
Shares
Fund managers
NameSinceBiography
Linden Thomson31/07/2015Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Prior to that she worked for Goldman Sachs on the sell side where she was based in the healthcare research team with specific focus on the biotechnology sector. She graduated from Edinburgh University with a BSc in Medical Microbiology and is a CFA Charterholder.
Dani Saurymper31/07/2015Dani Saurymper joined AXA IM in April 2015 as Portfolio Manager for the AXA Framlington Health funds. Dani has 14 years’ experience. Prior to joining AXA IM in April 2015 as Portfolio Manager, he was a senior equity research analyst covering European Healthcare at Barclays Capital. Dani started his career at Goldman Sachs as a senior pharmaceutical analyst covering European Pharmaceuticals, before moving to Nomura as a sector specialist covering global healthcare Dani graduated from Leeds University with a BSc in Management Studies and Pharmacology and holds an MSc in International Business from the Manchester School of Management, UMIST.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Transparent for German Tax, Reporting Fund Status, UCITS IV Compliant, MAS Unrestricted Scheme
Domicile
No data available.
Fund for sale in
Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Hong Kong, Italy, Luxembourg, Netherlands, Norway, Offshore, Portugal, Singapore, Sweden
AXA World Funds Framlington Health A Cap EUR
Initial charge5.5%
Annual charge1.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.01%
Total expense ratio (TER)1.89%
Bid price-
Offer price-
Mid price253.73
CurrencyEUR
Price updated28/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeK417
AXA World Funds Framlington Health A Cap SGD
Initial charge5.5%
Annual charge1.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.01%
Total expense ratio (TER)1.89%
Bid price-
Offer price-
Mid price132.83
CurrencySGD
Price updated28/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFK0W
AXA World Funds Framlington Health A Cap USD
Initial charge5.5%
Annual charge1.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.01%
Total expense ratio (TER)1.89%
Bid price-
Offer price-
Mid price210.99
CurrencyUSD
Price updated28/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeK416
AXA World Funds Framlington Health E Cap EUR
Initial charge-
Annual charge1.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.51%
Total expense ratio (TER)2.39%
Bid price-
Offer price-
Mid price241.45
CurrencyEUR
Price updated28/02/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeK419
AXA World Funds Framlington Health F Cap EUR
Initial charge2%
Annual charge0.9%
Min single investment£100,000
Min regular saving£5,000
Available in ISANo
Ongoing charge (OCF)1.16%
Total expense ratio (TER)1.04%
Bid price-
Offer price-
Mid price277.01
CurrencyEUR
Price updated28/02/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeK418
AXA World Funds Framlington Health F Cap USD
Initial charge2%
Annual charge0.9%
Min single investment£100,000
Min regular saving£5,000
Available in ISANo
Ongoing charge (OCF)1.17%
Total expense ratio (TER)1.03%
Bid price-
Offer price-
Mid price228.31
CurrencyUSD
Price updated28/02/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeK415
AXA World Funds Framlington Health M Cap EUR
Initial charge-
Annual charge-
Min single investment£10,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.17%
Total expense ratio (TER)0.11%
Bid price-
Offer price-
Mid price161.59
CurrencyEUR
Price updated28/02/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeFGFY
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.